Hijacking antibody-induced CTLA-4 lysosomal degradation for safer and more effective cancer immunotherapy
Sign Up to like & getrecommendations! Published in 2019 at "Cell Research"
DOI: 10.1038/s41422-019-0184-1
Abstract: It remains unclear why the clinically used anti-CTLA-4 antibodies, popularly called checkpoint inhibitors, have severe immunotherapy-related adverse effects (irAEs) and yet suboptimal cancer immunotherapeutic effects (CITE). Here we report that while irAE-prone Ipilimumab and TremeIgG1… read more here.
Keywords: anti ctla; ctla antibodies; ctla; cancer ... See more keywords
pH-sensitive anti-CTLA4 antibodies: yes to efficacy, no to toxicity
Sign Up to like & getrecommendations! Published in 2019 at "Cell Research"
DOI: 10.1038/s41422-019-0198-8
Abstract: For a long time, anti-CTLA-4 antibodies were believed to mediate their beneficial cancer immunotherapeutic effect (CITE), whose effectiveness and safety are limited by associated immune-related adverse effects (irAE), via blocking the interaction between CTLA-4 and… read more here.
Keywords: anti ctla; ctla antibodies; ctla; cancer ... See more keywords